FAILED TRIAL: Ph 2b SURVIVE Trial of SurVaxM in Newly Diagnosed GBM didn’t meet primary endpoint of OS improvement
Robert Fenstermaker, MD, co-principal investigator of the SURVIVE trial, Chair Emeritus of Neurosurgery at Roswell Park and Chief Medical Officer and Co-founder of MimiVax, added, “For patients 65 and under, this is one of the strongest signals we have seen in newly diagnosed glioblastoma in a long time. We designed the trial to provide a good comparison to our earlier Phase 2a study, while adding a placebo arm to account for improvements in standard of care that may have occurred over time. In a disease where progress has often been measured in weeks, results like these can be enormously meaningful.”
Share:
More News
“Identifying recurrence of colorectal cancer before it becomes clinically apparent, when it is potentially much easier to treat, is one of the central challenges in developing breakthrough therapies that help to answer unmet medical needs for this setting,” said Philippe P. Calais, PharmD, Ph.D., chairman and CEO, TransCode Therapeutics. “Leveraging
“The improvement in progression-free survival is a defining moment for RYZ101 and for the patients we built this program around — people with advanced GEP-NETs whose cancer has progressed after Lu177-based therapy and who have few remaining options,” said Amreen Husain, MD, chief medical officer of RayzeBio. “This is the
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated, “The FDA’s decision to grant Fast Track Designation just nine days after submission is an encouraging milestone for opamtistomig and our first-line BTC program. We appreciate the FDA’s engagement and its recommendation to initiate discussions on the U.S. registration strategy
“PI3Kα is one of the most important, well-validated, and heavily pursued disease drivers in oncology, but its therapeutic potential has been constrained by wild-type PI3Kα-mediated toxicity and incomplete coverage of clinically relevant mutations,” said Rob Kania, Ph.D., Chief Executive Officer of KymaThera. “Our drug design objective from the outset was